Published in Adv Cancer Res on January 01, 1972
Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. Ther Clin Risk Manag (2007) 0.93
Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. Proc Natl Acad Sci U S A (1996) 0.92
Repair of O6-(2-chloroethyl)guanine mediates the biological effects of chloroethylnitrosoureas. Environ Health Perspect (1985) 0.90
Difference in effect of single immunosuppressive agents (cyclophosphamide, CCNU, 5-FU) on peripheral blood immune cell parameters and central nervous system immunoglobulin synthesis rate in patients with multiple sclerosis. Clin Exp Immunol (1983) 0.83
Concurrent Chemotherapy of Malignant Glioma in Rats by Using Multidrug-Loaded Biodegradable Nanofibrous Membranes. Sci Rep (2016) 0.75
Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77
Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL/6 mice. Cancer Res (1984) 2.74
Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res (1975) 2.54
A clinical review of bleomycin--a new antineoplastic agent. Cancer (1973) 2.53
The antiviral activity of 9-beta-D-arabinofuranosyladenine (ARA-A). Chemotherapy (1968) 2.28
The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev (1975) 2.10
Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med (1973) 2.01
Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann Intern Med (1973) 1.87
In vivo antiviral properties of biologically active compounds. II. Studies with influenza and vaccinia viruses. Appl Microbiol (1968) 1.76
Adriamycin-a review. J Natl Cancer Inst (1975) 1.68
Experimental evaluation of potential anticancer agents. XXI. Scheduling of arabinosylcytosine to take advantage of its S-phase specificity against leukemia cells. Cancer Chemother Rep (1967) 1.65
Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules. Cancer Chemother Rep (1970) 1.54
cis-Dichlorodiammineplatinum(II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep (1980) 1.47
The chemotherapy of urologic cancer. Cancer (1975) 1.32
Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast. Cancer Treat Rev (1976) 1.31
Intensive chemotherapy of small cell bronchogenic carcinoma. Cancer Treat Rep (1977) 1.29
Carboplatin: the clinical spectrum to date. Cancer Treat Rev (1985) 1.27
The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol (1972) 1.24
Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res (1975) 1.22
Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med (1983) 1.19
Establishment of cross-resistance profiles for new agents. Cancer Treat Rep (1983) 1.18
Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res (1986) 1.17
Treatment of bronchogenic carcinoma. II. Small cell. Cancer Treat Rev (1977) 1.16
The dilemma of adjuvant chemotherapy for osteogenic sarcoma. Cancer Clin Trials (1980) 1.16
Purine analogs as potential anticytomegalovirus agents. Proc Soc Exp Biol Med (1969) 1.15
Quantitative studies on anaphylaxis in guinea-pigs passively sensitized with homologous antibody. Int Arch Allergy Appl Immunol (1971) 1.14
Management of locally advanced and disseminated breast cancer. Lancet (1981) 1.13
Rationale for adjuvant chemotherapy. Cancer (1977) 1.13
Success and failure in the treatment of solid tumors. I. Effects of cyclophosphamide (NSC-26271) on primary and metastatic plasmacytoma in the hamster. Cancer Chemother Rep (1968) 1.12
Experimental evaluation of potential anticancer agents. XVI. Basic study of effects of certain anticancer agents on kinetic behavior of model bacterial cell populations. Cancer Chemother Rep (1965) 1.12
Surgery plus adjuvant chemotherapy--a review of therapeutic implications. I. Breast cancer. Cancer Chemother Pharmacol (1980) 1.11
Studies on kallikrein: failure of some anti-inflammatory drugs to affect release of kinin. Br J Pharmacol Chemother (1966) 1.10
Concepts for systemic treatment of micrometastases. Cancer (1975) 1.09
A review of chemotherapy in gastric cancer. Cancer (1974) 1.09
Biology and therapeutic response of a mouse mammary adenocarcinoma (16/C) and its potential as a model for surgical adjuvant chemotherapy. Cancer Treat Rep (1978) 1.09
Antiviral agents as adjuncts in cancer chemotherapy. Pharmacol Ther (1980) 1.08
An overview of the 1978 international meeting on comparative therapeutic trials. Biomedicine (1978) 1.08
A comparison of the quality of participation of community affiliates and that of universities in the Northern California Oncology Group. J Clin Oncol (1983) 1.07
Single and combination nonhormonal chemotherapy in breast cancer. Cancer (1972) 1.06
Experiences in developing potential antiviral compounds. Ann N Y Acad Sci (1965) 1.06
Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinomas. Cancer (1977) 1.06
The use of tumor growth kinetics in planning "curative" chemotherapy of advanced solid tumors. Cancer Res (1969) 1.05
Transmucosal sustained-delivery of chlorpheniramine maleate in rabbits using a novel, natural mucoadhesive gum as an excipient in buccal tablets. Int J Pharm (1999) 1.04
The modes of decomposition of 1,3-bis(2-chloroethyl)-1-nitrosourea and related compounds. J Med Chem (1967) 1.04
On the carcinogenicity of a single intragastric dose of hydrocarbons, nitrosamines, aromatic amines, dyes, coumarins, and miscellaneous chemicals in female Sprague-Dawley rats. Cancer Res (1966) 1.03
Adjuvant chemotherapy in lung cancer: review and prospects. Cancer (1977) 1.02
Glutamine antagonists in chemotherapy. Adv Pharmacol Chemother (1970) 1.01
Metabolism and chemotherapeutic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine against murine leukemia L1210 and evidence for its phosphorylation by deoxycytidine kinase. Cancer Res (1980) 1.01
Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer (1976) 1.00
Nitrosoureas: a review of experimental antitumor activity. Cancer Treat Rep (1976) 1.00
Poloxamer 407-induced atherogenesis in the C57BL/6 mouse. Atherosclerosis (1998) 0.99
3-Deazauridine: inhibition of ribonucleic acid virus-induced cytopathogenic effects in vitro. Antimicrob Agents Chemother (1972) 0.99
Calibrated phase II clinical trials in oncology. Stat Med (1987) 0.99
Antiviral activity of 9-beta-D-arabinofuranosyladenine. II. Activity against Herpes simplex keratitis in hamsters. Antimicrob Agents Chemother (Bethesda) (1968) 0.99
Management of trials in the development of cancer chemotherapy. Br J Cancer (1978) 0.99
Transmucosal delivery of oxytocin to rabbits using a mucoadhesive buccal patch. Pharm Dev Technol (1997) 0.98
Patterns of resistance and therapeutic synergism among alkylating agents. Antibiot Chemother (1971) (1978) 0.98
Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev (1974) 0.98
5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma. Eur J Cancer (1972) 0.97
Experimental therapeutics and kinetics: selection and overgrowth of specifically and permanently drug-resistant tumor cells. Semin Hematol (1978) 0.97
Nafoxidine--an antiestrogen for the treatment of breast cancer. Cancer (1976) 0.96
Biologic activity of 9-beta-D-arabinofuranosyl-2-fluoroadenine, a metabolically stable analog of 9-beta-D-arabinofuranosyladenine. Biochem Pharmacol (1977) 0.96
Editorial: Large-bowel cancer-The current status of treatment. J Natl Cancer Inst (1976) 0.94
Relationship of structure to anticancer activity and toxicity of the nitrosoureas in animal systems. Cancer Treat Rep (1986) 0.94
Evaluation of the gum from Hakea gibbosa as a sustained-release and mucoadhesive component in buccal tablets. Pharm Dev Technol (1999) 0.93
Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors. Cancer Res (1975) 0.93
Cisplatin-induced autonomic neuropathy. Cancer Treat Rep (1984) 0.93
Toxicity studies in mice treated with 1-beta-D-arabinofuranosylcytosine (ara-C). Cancer Res (1969) 0.93
Comparison of the properties of metabolites of CCNU. Biochem Pharmacol (1977) 0.92
Experimental evaluation of potenital anticancer agents. XVII. Kinetics of growth and regression after treatment of certain solid tumors. Cancer Chemother Rep (1965) 0.92
Patterns of failure in small cell carcinoma of the lung. Cancer (1982) 0.92
Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res (1982) 0.91
Combination chemotherapy of advanced Hodgkin's disease. A review. Cancer (1974) 0.91
Toxicological evaluation of poloxamer vehicles for intramuscular use. J Parenter Sci Technol (1985) 0.91
Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat. J Pharm Sci (1992) 0.91
Macromolecular binding and metabolism of the carcinogen 1,2-dibromoethane. Cancer Res (1978) 0.90
Experimental evaluation of potential anticancer agents. 28. Effects of therapy on viability and rate of proliferation of leukemic cells in various anatomic sites. Cancer Chemother Rep (1965) 0.90
Spontaneous AK leukemia (lymphoma) as a model system. Cancer Chemother Rep (1969) 0.89
Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol (1987) 0.89
Streptozotocin and metastatic insulinoma. Ann Intern Med (1971) 0.89
Evaluation of a mucoadhesive buccal patch for delivery of peptides: in vitro screening of bioadhesion. Drug Dev Ind Pharm (1998) 0.89
Calcitonin as a marker for bronchogenic cancer: a prospective study. Cancer (1979) 0.88
Inhibition of ribonucleotide reductase, DNA synthesis, and L1210 leukemia by guanazole. Cancer Res (1970) 0.88
Investigational drugs under study by the United States National Cancer Institute. Cancer Treat Rev (1976) 0.88
The nitrosoureas--thoughts for the future. Cancer Treat Rep (1976) 0.88
A quick reference chart on cross resistance between anticancer patients. Cancer Chemother Rep (1972) 0.88
The poloxamer 407-induced hyperlipidemic atherogenic animal model. Med Sci Sports Exerc (1997) 0.87
Antiviral activity of carbobenzosy di- and tripeptides on measles virus. Appl Microbiol (1968) 0.87
An overview of the status of the nitrosoureas in other tumors. Cancer Chemother Rep 3 (1973) 0.87
The chemotherapy of prostatic adenocarcinoma. Ann Intern Med (1980) 0.87
Experimental studies of the antitumor activity of amygdalin MF (NSC-15780) alone and in combination with beta-glucosidase (NSC-128056). Cancer Chemother Rep (1976) 0.86
Clinical comparison of the nitrosoureas. Cancer (1975) 0.86
Antiestrogens in the treatment of breast cancer. Cancer Treat Rev (1976) 0.86
The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck. Cancer Treat Rev (1975) 0.86
The California breast cancer law and government-mandated patient education. CA Cancer J Clin (1982) 0.86
Population-based study of small-cell lung cancer. J Clin Oncol (1985) 0.86
The integration of chemotherapy into combined modality treatment of solid tumors. VIII. Cervical cancer. Cancer Treat Rev (1977) 0.86
Clinical concepts derived from animal chemotherapy studies. Cancer Treat Rep (1981) 0.86